JUXTAPID (lomitapide mesylate)
MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITORS · HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
AMRYT/CHIESI
Drug class
Microsomal Triglyceride Transfer Protein Inhibitors
Microsomal triglyceride transfer protein inhibitors are a specialized class of lipid-lowering agents designed to reduce circulating atherogenic lipoproteins. Read more about Microsomal Triglyceride Transfer Protein Inhibitors
2 drugs in this class 2 manufacturers
Drugs in Microsomal Triglyceride Transfer Protein Inhibitors
JUXTAPID (lomitapide mesylate)
MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITORS · HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
CHIESI USA, INC
Filter & compare in the drug finder →
Opens the drug finder with Microsomal Triglyceride Transfer Protein Inhibitors preselected. Add indication or manufacturer filters there.
Microsomal triglyceride transfer protein inhibitors are a specialized class of lipid-lowering agents designed to reduce circulating atherogenic lipoproteins.
They function by inhibiting microsomal triglyceride transfer protein within the endoplasmic reticulum of hepatocytes and enterocytes, preventing the assembly and secretion of apolipoprotein B–containing lipoproteins, including very low-density lipoproteins and chylomicrons.
This mechanism bypasses the low-density lipoprotein receptor pathway to produce substantial reductions in plasma low-density lipoprotein cholesterol and triglyceride concentrations.
Clinically, this drug class is primarily indicated as an adjunct to diet and other lipid-lowering therapies for the management of homozygous familial hypercholesterolemia.
-
rxlist.com
Microsomal triglyceride transfer protein inhibitors are a specialized class of lipid-lowering agents designed to reduce circulating atherogenic lipoproteins They function by inhibiting microsomal triglyceride transfer protein within the endoplasmic reticulum of hepatocytes and enterocytes, preventing the assembly and secretion of apolipoprotein B–containing lipoproteins, including very low-density lipoproteins and chylomicrons This mechanism bypasses the low-density lipoprotein receptor pathway ...
-
patsnap.com
They function by inhibiting microsomal triglyceride transfer protein within the endoplasmic reticulum of hepatocytes and enterocytes, preventing the assembly and secretion of apolipoprotein B–containing lipoproteins, including very low-density lipoproteins and chylomicrons
-
imrpress.com
This mechanism bypasses the low-density lipoprotein receptor pathway to produce substantial reductions in plasma low-density lipoprotein cholesterol and triglyceride concentrations Clinically, this drug class is primarily indicated as an adjunct to diet and other lipid-lowering therapies for the management of homozygous familial hypercholesterolemia
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.